Ivacaftor: Long term adherence and outcomes
Thorax Podcast
English - March 26, 2021 16:58 - 11 minutes - 10.3 MB - ★★★★ - 1 ratingScience Health & Fitness Medicine medicine health interviews bmj debates conference roundtable british medical journal Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Meat Consumption and Childhood Wheeze: The implications of Western Diet
Next Episode: The SUR-VAPES Study
The recent development of triple CFTR modulation means that up to 90% of people with CF will be eligible for ‘highly effective’ CFTR modulator therapy. In this podcast, Rachael Moses, Multimedia Editor of Thorax, and Dr Peter Barry, Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre, discuss the long-term adherence to and effects of ivacaftor on lung function, weight and healthcare utilisation in people with cystic fibrosis and the Gly551Asp mutation.
Read the related paper: https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215556